Higher Drug Sales Buoy Amgen Results

Amgen said its earnings, excluding restructuring charges, increased more than expected in the third quarter, driven by strong growth of key drugs such as cancer therapy Krypolis and osteoporosis treatment Prolia.



from WSJ.com: US Business http://ift.tt/ZV84Wq

via IFTTT